Tolinapant not checked

Taiho Oncology, Inc. · Astex Pharmaceuticals, Inc. · ASTX660

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
5 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Solid Tumors, Lymphoma
Main trialPhase 1/2
“This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.”In the company’s words, NCT02503423 on ClinicalTrials.gov
Other names
ASTX660

Other drugs for Solid Tumors

All 2439 drugs for Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting Oct 2022 Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Phase 1Completed 23 Aug 2020 A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
Phase 1Completed 25 Aug 2020 Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
Phase 1Terminated 14 Jan 2022 A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1Terminated 16 Dec 2024 A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Tolinapant

Following is part of Solo: you see every change to Tolinapant the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in